JAK2 and COVID-19: Baricitinib is a selective inhibitor of JAK1 and JAK2 and believed to interfere with the signaling of key cytokines that are produced abundantly in COVID-19, including IL-2, IL-6, IL-7, and granulocyte monocyte colony-stimulating factor [94].